Clinical Trials - Planning, Implementation and Monitoring
Swiss TPH has a broad expertise in clinical trials. We are dedicated to the design, implementation, management and monitoring of clinical trials (Phase I to Phase IV and implementation) on poverty related diseases in resource-constrained countries and settings. We have acquired a significant wealth of experience in conducting complex clinical trials exposed to a multitude of cultural, scientific and operational challenges, and have access to a worldwide network of partners and collaborators.
Strengthening Local Capacities
In developing countries and particularly rural areas, adequate capacities including human resources and infrastructure may not always be guaranteed to facilitate clinical trials up to regulatory standard. Maximizing safety and finding sustainable long-term solutions can translate into building infrastructure, strengthening local know-how by offering expertise, building capacity and empowering local and existing partners.
The DRC Hub
To support our growing number of projects in the Democratic Republic of the Congo (DRC), we have established and registered as an NGO in the DRC since July 2015. The office serves as the local representation of the Clinical Operations Unit and is the basis for a broad spectrum of activities in both clinical research and public health.
Swiss TPH also maintains a project office in Bukavu, supporting capacity building and research projects in the East of the DRC.
The past and current project portfolio in the DRC comprises epidemiological research projects, capacity strengthening activities in public health and malaria, clinical trials on human African trypanosomiasis (sleeping sickness) and malaria in both paediatric and adult populations. The Swiss TPH office is also the basis of the Alliance for Clinical Research and Clinical Epidemiology in the DRC (ARCEAU-RDC) and our direct link to the various partner organisations and clients in the DRC.
Fexinidazole against African Human Trypanosomiasis
Human Africa Trypanosomiasis is a life-threatening neglected disease. To date nifurtimox-eflornithine combined therapy (NECT) is the Standard Treatment for late-stage HAT. Nevertheless, NECT is still far from ideal given the environment in which HAT patients live. There is an urgent need to develop less toxic and easier-to-use products. One promising agent is Fexinidazole. Read more about the project
Pediatric Praziquantel Formulation for Treating Schistosomiasis
Schistosomes, parasitic blood flukes, cause the chronic disaese schistosomiasis. Today, the gold standard of treatment is praziquantel which is only suitable for adults and school-aged children. Thus, a palliative, effective and safe praziquantel formulation to treat young children is absolutely required. To reach this aim, the Pediatric Praziquantel Consortium was founded in 2012. Read more about the project
Treatment of Multidrug-Resistant Tuberculosis
Tuberculosis is one of the most deadly infectious diseases in the world. Treatment is complex especially in case of multidrug-resistant tuberculosis. Particularly patients in low-resource countries often lack access or do not complete treatment regimen. TB PRACTECAL is a pioneering new clinical trial aiming to find a radically improved course of treatment for drug-resistant tuberculosis. Read more about the project